All sponsors

BioMarin Pharmaceutical $BMRN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-35
RECRUITING3
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO60%

Delay Index: of 10 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →

Open BioMarin Pharmaceutical on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
PEGASUS
NCT05270837
P3Active, not recruitingPhenylketonuria (PKU)552025-01-14 (-11 mo)
GENEr8-JPN
NCT06224907
P3Active, not recruitingHemophilia A62025-04-16 (+2 mo)
Vosoritide Injection
NCT06382155
P2RecruitingIdiopathic Short Stature1002026-06
BMN 351
NCT06280209
P1/2Active, not recruitingDuchenne Muscular Dystrophy182027-04-14 (+16 mo)
BMN 307
NCT04480567
P1/2Active, not recruitingPhenylketonuria (PKU)1002027-12 (+12 mo)
ACH
NCT02724228
P2Active, not recruitingAchondroplasia302027-12 (+62 mo)
vosoritide
NCT04554940
P2Active, not recruitingAchondroplasia202027-12 (+12 mo)
Vosoritide
NCT07126262
P2RecruitingHypochondroplasia602028-06-30
HAErmony-1
NCT05121376
P1/2Active, not recruitingHereditary Angioedema; HAE442028-11
ASPEN
NCT07441876
P2/3RecruitingAchondroplasia1602029-06
BMN 111
NCT03424018
P3Active, not recruitingAchondroplasia1192031-06 (+80 mo)
BMN 351
NCT07573631
P2Enrolling by invitationDuchenne Muscular Dystrophy (DMD)182031-12
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
NCT03989947
P2Active, not recruitingAchondroplasia732038-05
CANOPY-HCH-EXT
NCT07073014
P3Enrolling by invitationHypochondroplasia1402044-10 (+46 mo)